Zinātniskās darbības atbalsta sistēma
Latviešu English

Publikācija: Azole-Based Non-Peptidomimetic Plasmepsin Inhibitors

Publikācijas veids Zinātniskais raksts, kas indeksēts Web of science un/vai Scopus datu bāzē
Pamatdarbībai piesaistītais finansējums ES struktūrfondi
Aizstāvēšana: ,
Publikācijas valoda English (en)
Nosaukums oriģinālvalodā Azole-Based Non-Peptidomimetic Plasmepsin Inhibitors
Pētniecības nozare 1. Dabaszinātnes
Pētniecības apakšnozare 1.4. Ķīmija
Autori L. Kinena
G. Leitis
I. Kanepe-Lapsa
R. Bobrovs
Kristaps Jaudzems
V. Ozola
Edgars Sūna
Aigars Jirgensons
Atslēgas vārdi bioisosteric replacement, inhibitor, malaria | plasmepsins, Plasmodium falciparum, triazole
Anotācija The spread of drug-resistant malaria parasites urges the search for new antimalarial drugs. Malarial aspartic proteases – plasmepsins (Plms) – are differentially expressed in multiple stages of the Plasmodium parasite's lifecycle and are considered as attractive drug targets. We report the development of novel azole-based non-peptidomimetic plasmepsin inhibitors that have been designed by bioisosteric substitution of the amide moiety in the Actelion amino-piperazine inhibitors. The best triazole-based inhibitors show submicromolar potency toward Plm II, which is comparable to that of the parent Actelion compounds. The new inhibitors can be used as a starting point for the development of a resistance-free antimalarial drug targeting the non-digestive Plm IX or X, which are essential for the malaria parasite life cycle.
DOI: 10.1002/ardp.201800151
Atsauce Kinena, L., Leitis, G., Kanepe-Lapsa, I., Bobrovs, R., Jaudzems, K., Ozola, V., Sūna, E., Jirgensons, A. Azole-Based Non-Peptidomimetic Plasmepsin Inhibitors. Archiv der Pharmazie, 2018, Vol.351, 1800151a.-1800151b.lpp. ISSN 0365-6233. Pieejams: doi:10.1002/ardp.201800151
Papildinformācija Citējamību skaits:
ID 28471